CoChat
Sign Up
Cited by 22

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Cyclic RGD-Functionalized pH/ROS Dual-Responsive Nanoparticle for Targeted Breast Cancer Therapy

Yao, Pu, Wang, Xiaowen, Wang, Qianmei, Dai, Qing, Peng, Yu, Yuan, Qian, Mou, Nan, Lv, Shan, Weng, Bangbi, Wang, Yu, Sun, Fengjun·2023·Pharmaceutics
DOI 10.3390/pharmaceutics15071827PMC PMC10386338
Open this paper in CoChat — free account

Abstract

Breast cancer is the most common malignant tumor in women and is a big challenge to clinical treatment due to the high morbidity and mortality. The pH/ROS dual-responsive nanoplatforms may be an effective way to significantly improve the therapeutic efficacy of breast cancer. Herein, we report a docetaxel (DTX)-loaded pH/ROS-responsive NP that could achieve active targeting of cancer cells and selective and complete drug release for effective drug delivery. The pH/ROS-responsive NPs were fabricated using nanocarriers that consist of an ROS-responsive moiety (4-hydroxymethylphenylboronic acid pinacol ester, HPAP), cinnamaldehyde (CA, an aldehyde organic compound with anticancer activities) and cyclodextrin (α-CD). The NPs were loaded with DTX, modified with a tumor-penetration peptide (circular RGD, cRGD) and named DTX/RGD NPs. The cRGD could promote DTX/RGD NPs penetration into deep tumor tissue and specifically target cancer cells. After internalization by cancer cells through receptor-mediated endocytosis, the pH-responsive acetal was cleaved to release CA in the lysosomal acidic environment. Meanwhile, the high ROS in tumor cells induced the disassembly of NPs with complete release of DTX. In vitro cellular assays verified that DTX/RGD NPs could be effectively internalized by 4T1 cells, obviously inducing apoptosis, blocking the cell cycle of 4T1 cells and consequently, killing tumor cells. In vivo animal experiments demonstrated that the NPs could target to the tumor sites and significantly inhibit the tumor growth in 4T1 breast cancer mice. Both in vitro and in vivo investigations demonstrated that DTX/RGD NPs could significantly improve the antitumor effect compared to free DTX. Thus, the DTX/RGD NPs provide a promising strategy for enhancing drug delivery and cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics15071827

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fabrication of DTX-loaded pH/ROS dual-responsive NPs for targeted breast cancer therapy.
Figure 1 Fabrication of DTX-loaded pH/ROS dual-responsive NPs for targeted breast cancer therapy.CC BY · PubMed Central
Figure 2 Characterization of DTX/RGD NPs. (A) The size distribution of NPs determined with DLS. (B) The morphology of NPs observed with TEM. Scale bar represents 0.5 μm. (C) The hemolytic activity of NPs at various concentrations. (D) The in vitro drug-release behavior of DTX from NPs in various release media within 48 h. Each value represents the mean ± SD (n = 3).
Figure 2 Characterization of DTX/RGD NPs. (A) The size distribution of NPs determined with DLS. (B) The morphology of NPs observed with TEM. Scale bar represents 0.5 μm. (C) The hemolytic activity of NPs at various concentrations. (D) The in vitro drug-release behavior of DTX from NPs in various release media within 48 h. Each value represents the mean ± SD (n = 3).CC BY · PubMed Central
Figure 3 Cellular uptake of Cy5-labeled NPs in 4T1 cells and fluorescence distribution of Cy5-labeled NPs in 4T1 tumor spheroids. (A) The CLSM images of cellular uptake of Cy5-labeled NPs in 4T1 cells after 4 h treatment. Cell nuclei were stained with DAPI (blue), FITC-phalloidin for cytoskeleton staining (green) and Cy5-labeled NPs (red). Scale bar represents 20 μm. (B) Fluorescence distribution of Cy5-labeled NPs (red) in 4T1 tumor spheroids after 4 h treatment. Cell nuclei were stained with DAPI (blue) and Cy5-labeled NPs (red). Scale bar represents 50 μm.
Figure 3 Cellular uptake of Cy5-labeled NPs in 4T1 cells and fluorescence distribution of Cy5-labeled NPs in 4T1 tumor spheroids. (A) The CLSM images of cellular uptake of Cy5-labeled NPs in 4T1 cells after 4 h treatment. Cell nuclei were stained with DAPI (blue), FITC-phalloidin for cytoskeleton staining (green) and Cy5-labeled NPs (red). Scale bar represents 20 μm. (B) Fluorescence distribution of Cy5-labeled NPs (red) in 4T1 tumor spheroids after 4 h treatment. Cell nuclei were stained with DAPI (blue) and Cy5-labeled NPs (red). Scale bar represents 50 μm.CC BY · PubMed Central
Figure 4 The in vitro antitumor activities of NPs against 4T1 cells. (A) Cell viabilities of 4T1 cells after treatment with blank NPs, DTX and DTX-loaded NPs at various drug concentration for 24 h. (B) Cell viabilities of 4T1 cells after treatment with blank NPs, DTX and DTX-loaded NPs at various drug concentrations for 48 h. (C) Quantitative analysis of cell-cycle profiles of 4T1 cells following treatment with blank NPs, DTX and DTX-loaded NPs for 48 h. (D) The apoptotic percentages of 4T1 cells following treatment with blank NPs, DTX and DTX-loaded NPs for 48 h. Each value represents the mean ± SD (n = 3). *, statistically different at p < 0.05; **, statistically different at p < 0.01; ***, statistically different at p < 0.001, compared with DTX/RGD NPs.
Figure 4 The in vitro antitumor activities of NPs against 4T1 cells. (A) Cell viabilities of 4T1 cells after treatment with blank NPs, DTX and DTX-loaded NPs at various drug concentration for 24 h. (B) Cell viabilities of 4T1 cells after treatment with blank NPs, DTX and DTX-loaded NPs at various drug concentrations for 48 h. (C) Quantitative analysis of cell-cycle profiles of 4T1 cells following treatment with blank NPs, DTX and DTX-loaded NPs for 48 h. (D) The apoptotic percentages of 4T1 cells following treatment with blank NPs, DTX and DTX-loaded NPs for 48 h. Each value represents the mean ± SD (n = 3). *, statistically different at p < 0.05; **, statistically different at p < 0.01; ***, statistically different at p < 0.001, compared with DTX/RGD NPs.CC BY · PubMed Central
Figure 5 In vivo biodistribution of free Cy5, Cy5-labeled NPs and Cy5-labeled RGD NPs in 4T1 tumor-bearing mice. (A) In vivo fluorescence images of mice 2 h, 8 h, 24 h and 48 h after administration. Normal mice were injected with saline. (B) Ex vivo fluorescence image of the excised major tissues and tumors at 48 h post-injection. (C) Semi-quantitative analysis of fluorescence intensity in tumor tissues at the indicated time points. (D) Semi-quantitative analysis of fluorescence intensity of tumors excised from mice. *, statistically different at p < 0.05; **, statistically different at p < 0.01; ***, statistically different at p < 0.001, compared with Cy5-labeled RGD NPs.
Figure 5 In vivo biodistribution of free Cy5, Cy5-labeled NPs and Cy5-labeled RGD NPs in 4T1 tumor-bearing mice. (A) In vivo fluorescence images of mice 2 h, 8 h, 24 h and 48 h after administration. Normal mice were injected with saline. (B) Ex vivo fluorescence image of the excised major tissues and tumors at 48 h post-injection. (C) Semi-quantitative analysis of fluorescence intensity in tumor tissues at the indicated time points. (D) Semi-quantitative analysis of fluorescence intensity of tumors excised from mice. *, statistically different at p < 0.05; **, statistically different at p < 0.01; ***, statistically different at p < 0.001, compared with Cy5-labeled RGD NPs.CC BY · PubMed Central
Figure 6 In vivo antitumor efficacy evaluation of blank NPs, DTX and various DTX-loaded NPs in 4T1 tumor-bearing mice. (A) The administration time after tumor inoculation. Mice received 5 mg/kg of DTX or 5 mg/kg of various DTX-loaded NPs via vein every four days for five times. (B) The body weight changes of mice following different treatment (n = 6). (C) Representative photographs of tumor tissues of mice following different treatment. (D) The tumor growth curves of mice following different treatment (n = 6). (E) Individual tumor volumes of mice following different treatments. The ratio refers to the proportion of mice with tumors that exceed 600 mm3 on day 20. (F) The tumor weight of mice following different treatments. (G) The DTX concentration in tumor tissues of mice following different treatments (n = 3). (H) The photo images of collected lungs in the mice following different treatments on day 20. *, statistically different at p < 0.05; **, statistically different at p < 0.01; ***, statistically different at p < 0.001, compared with DTX/RGD NPs.
Figure 6 In vivo antitumor efficacy evaluation of blank NPs, DTX and various DTX-loaded NPs in 4T1 tumor-bearing mice. (A) The administration time after tumor inoculation. Mice received 5 mg/kg of DTX or 5 mg/kg of various DTX-loaded NPs via vein every four days for five times. (B) The body weight changes of mice following different treatment (n = 6). (C) Representative photographs of tumor tissues of mice following different treatment. (D) The tumor growth curves of mice following different treatment (n = 6). (E) Individual tumor volumes of mice following different treatments. The ratio refers to the proportion of mice with tumors that exceed 600 mm3 on day 20. (F) The tumor weight of mice following different treatments. (G) The DTX concentration in tumor tissues of mice following different treatments (n = 3). (H) The photo images of collected lungs in the mice following different treatments on day 20. *, statistically different at p < 0.05; **, statistically different at p < 0.01; ***, statistically different at p < 0.001, compared with DTX/RGD NPs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 43

  1. Davodabadi, 2022, Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches, J. Control. Release Off. J. Control. Release Soc., 349, 844, 10.1016/j.jconrel.2022.07.036 · DOI
  2. Bahreyni, 2020, Emerging nanomedicines for effective breast cancer immunotherapy, J. Nanobiotechnol., 18, 180, 10.1186/s12951-020-00741-z · DOI
  3. Britt, 2020, Key steps for effective breast cancer prevention, Nat. Rev. Cancer, 20, 417, 10.1038/s41568-020-0266-x · DOI · Paper page
  4. Lau, K.H., Tan, A.M., and Shi, Y. (2022). New and Emerging Targeted Therapies for Advanced Breast Cancer. Int. J. Mol. Sci., 23. · DOI
  5. Yao, 2016, Ligand-targeted theranostic nanomedicines against cancer, J. Control. Release Off. J. Control. Release Soc., 240, 267, 10.1016/j.jconrel.2016.01.002 · DOI
  6. Aleksandrowicz, 2017, Drug delivery systems improving chemical and physical properties of anticancer drugs currently investigated for treatment of solid tumors, J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc., 68, 165
  7. de la Torre, P., Perez-Lorenzo, M.J., Alcazar-Garrido, A., and Flores, A.I. (2020). Cell-Based Nanoparticles Delivery Systems for Targeted Cancer Therapy: Lessons from Anti-Angiogenesis Treatments. Molecules, 25. · DOI
  8. Seyyednia, 2021, Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging, J. Control. Release Off. J. Control. Release Soc., 338, 367, 10.1016/j.jconrel.2021.08.044 · DOI
  9. Yu, 2022, Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy, Biomaterials, 280, 121312, 10.1016/j.biomaterials.2021.121312 · DOI
  10. Amreddy, 2018, Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery, Adv. Cancer Res., 137, 115, 10.1016/bs.acr.2017.11.003 · DOI
  11. Wang, 2010, Targeting nanoparticles to cancer, Pharmacol. Res., 62, 90, 10.1016/j.phrs.2010.03.005 · DOI
  12. Jiang, 2019, Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors, Biomaterials, 192, 292, 10.1016/j.biomaterials.2018.11.021 · DOI
  13. Zhang, 2022, Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy, Biomaterials, 291, 121906, 10.1016/j.biomaterials.2022.121906 · DOI
  14. Zhou, 2018, Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance, Theranostics, 8, 1059, 10.7150/thno.22679 · DOI
  15. Antoniou, 2021, Stimulus-responsive liposomes for biomedical applications, Drug Discov. Today, 26, 1794, 10.1016/j.drudis.2021.05.010 · DOI
  16. Huu, 2015, Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye, J. Control. Release Off. J. Control. Release Soc., 200, 71, 10.1016/j.jconrel.2015.01.001 · DOI
  17. Li, 2021, Magnetic nanoparticles for cancer theranostics: Advances and prospects, J. Control. Release Off. J. Control. Release Soc., 335, 437, 10.1016/j.jconrel.2021.05.042 · DOI
  18. Sun, 2022, Self-Illuminating Triggered Release of Therapeutics from Photocleavable Nanoprodrug for the Targeted Treatment of Breast Cancer, ACS Appl. Mater. Interfaces, 14, 8766, 10.1021/acsami.1c21665 · DOI
  19. Cheng, 2022, A pH-Responsive Cluster Metal-Organic Framework Nanoparticle for Enhanced Tumor Accumulation and Antitumor Effect, Adv. Mater., 34, e2203915, 10.1002/adma.202203915 · DOI
  20. Shahriari, 2019, Enzyme responsive drug delivery systems in cancer treatment, J. Control. Release Off. J. Control. Release Soc., 308, 172, 10.1016/j.jconrel.2019.07.004 · DOI
  21. Xu, 2021, Development of ROS-responsive amino acid-based poly(ester amide) nanoparticle for anticancer drug delivery, J. Biomed. Mater. Res. Part A, 109, 524, 10.1002/jbm.a.37035 · DOI
  22. Ye, 2017, A Tumor-Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers, Adv. Mater., 29, 1702342, 10.1002/adma.201702342 · DOI
  23. Wang, 2019, Self-Strengthened Oxidation-Responsive Bioactivating Prodrug Nanosystem with Sequential and Synergistically Facilitated Drug Release for Treatment of Breast Cancer, ACS Appl. Mater. Interfaces, 11, 18914, 10.1021/acsami.9b03056 · DOI
  24. Zhang, H., Ma, W., Wang, Z., Wu, X., Zhang, H., Fang, W., Yan, R., and Jin, Y. (2022). Self-Supply Oxygen ROS Reactor via Fenton-like Reaction and Modulating Glutathione for Amplified Cancer Therapy Effect. Nanomaterials, 12. · DOI
  25. Tu, 2022, Cinnamaldehyde-based poly(thioacetal): A ROS-awakened self-amplifying degradable polymer for enhanced cancer immunotherapy, Biomaterials, 289, 121795, 10.1016/j.biomaterials.2022.121795 · DOI
  26. Zhang, 2018, An Adenosine Triphosphate-Responsive Autocatalytic Fenton Nanoparticle for Tumor Ablation with Self-Supplied H2O2 and Acceleration of Fe(III)/Fe(II) Conversion, Nano Lett., 18, 7609, 10.1021/acs.nanolett.8b03178 · DOI
  27. Miyanaga, 2016, Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells, Int. J. Oncol., 48, 517, 10.3892/ijo.2015.3291 · DOI
  28. Xu, 2015, Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer, Biomaterials, 64, 10, 10.1016/j.biomaterials.2015.06.017 · DOI
  29. Torchilin, 2011, Tumor delivery of macromolecular drugs based on the EPR effect, Adv. Drug Deliv. Rev., 63, 131, 10.1016/j.addr.2010.03.011 · DOI
  30. Chen, 2016, Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3, Theranostics, 6, 78, 10.7150/thno.13242 · DOI
  31. Liu, 2016, Integrin (αvβ3) Targeted RGD Peptide Based Probe for Cancer Optical Imaging, Curr. Protein Pept. Sci., 17, 570, 10.2174/1389203717666160101124015 · DOI
  32. Perrins, R.D., McCarthy, L.A., Robinson, A., Spry, K.L., Cognet, V., Ferreira, A., Porter, J., Garciotaa, C.E., Rodriguez, M.A., and Lopez, D. (2022). Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload. Nanomaterials, 12. · DOI
  33. Yang, 2011, cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging, Biomaterials, 32, 4151, 10.1016/j.biomaterials.2011.02.006 · DOI
  34. Wang, 2019, cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer, Acta Biomater., 94, 495, 10.1016/j.actbio.2019.06.039 · DOI
  35. Capello, 2006, Anticancer activity of targeted proapoptotic peptides, J. Nucl. Med. Off. Publ. Soc. Nucl. Med., 47, 122
  36. Gu, 2022, αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma, J. Nanobiotechnol., 20, 384, 10.1186/s12951-022-01597-1 · DOI · Paper page
  37. Zhao, 2015, A preloaded amorphous calcium carbonate/doxorubicin@silica nanoreactor for pH-responsive delivery of an anticancer drug, Angew. Chem., 54, 919, 10.1002/anie.201408510 · DOI
  38. Yang, 2016, Dual Stimuli-Responsive Hybrid Polymeric Nanoparticles Self-Assembled from POSS-Based Starlike Copolymer-Drug Conjugates for Efficient Intracellular Delivery of Hydrophobic Drugs, ACS Appl. Mater. Interfaces, 8, 13251, 10.1021/acsami.6b02403 · DOI
  39. Deng, 2019, Rational Design of Nanoparticles to Overcome Poor Tumor Penetration and Hypoxia-Induced Chemotherapy Resistance: Combination of Optimizing Size and Self-Inducing High Level of Reactive Oxygen Species, ACS Appl. Mater. Interfaces, 11, 31743, 10.1021/acsami.9b12129 · DOI
  40. Wang, 2021, Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment, Drug Deliv., 28, 1695, 10.1080/10717544.2021.1963351 · DOI
  41. Morarasu, S., Morarasu, B.C., Ghiarasim, R., Coroaba, A., Tiron, C., Iliescu, R., and Dimofte, G.M. (2022). Targeted Cancer Therapy via pH-Functionalized Nanoparticles: A Scoping Review of Methods and Outcomes. Gels, 8. · DOI
  42. Farjadian, 2022, Physically stimulus-responsive nanoparticles for therapy and diagnosis, Front. Chem., 10, 952675, 10.3389/fchem.2022.952675 · DOI
  43. Zhang, 2019, Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy, Nat. Commun., 10, 1704, 10.1038/s41467-019-09566-3 · DOI

Cited by

Sorted by citations

See all 22

Metadata

Authors
Yao, P., Wang, X., Wang, Q., Dai, Q., Peng, Y., Yuan, Q., Mou, N., Lv, S., Weng, B., Wang, Y., & Sun, F.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2023-06-26
Volume
15
Issue
7
Pages
1827
ISSN
1999-4923
DOI
10.3390/pharmaceutics15071827
PMC
PMC10386338
Cited by
22
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Natural Science Foundation of China (82102448, cstc2015zdcy-ztzx120005)
  • Special Project of Common Key Technology Innovation for Key Industries in Chongqing (82102448, cstc2015zdcy-ztzx120005)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review